Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

Abstract

Neoadjuvant combination of trastuzumab and chemotherapy resulted in a high pCR rate in HER2-overexpressing primary breast cancer. Patients with a pCR after neoadjuvant anti-HER2 therapy in combination with chemotherapy followed by maintenance trastuzumab have an improved long-term outcome. Patients without a pCR had an increased risk for relapse and death.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

“…Also, to our knowledge, this is the first trial to correlate pCR with survival outcomes in women treated with dual anti-HER2 drugs (lapatinib plus trastuzumab). Other trials have also shown that patients treated with neoadjuvant chemotherapy and trastuzumab and experiencing pCR have better survival outcomes compared to no pCR (16)(17)(18). The NOAH trial showed that patients treated with neoadjuvant trastuzumab and experiencing pCR had a better EFS compared to those without pCR after a median follow-up of 5·4 years (hazard ratio 0·17; 95%CI 0·08-0·38; p<0·0001) (19).…”

Inmunohistoquímica convencional como predictor de respuesta y sobrevida en pacientes con cáncer de mama tratadas con quimioterapia preoperatoria: Experiencia de un centro

“…Pacientes con respuesta parcial o sin respuesta fueron clasificados como "no-RPC". Debido a que la definición exacta de RPC se encuentra aún en discusión, exploramos una segunda definición (RPC-2) definida como Triple Negativo 25,0% (6) para tumores con baja tasa de proliferación. Esta diferencia no fue estadísticamente significativa (p = 0,11).…”

“…Después de QTN, tumores considerados basaloides (la mayoría TN) o HER-2 positivos logran mayor RPC que aquellos considerados luminales (estrógenos dependientes). Este último factor, la obtención de RPC, se asocia a mejor sobrevida, que aquellos que no alcanzan tal respuesta 6,7 . Sin embargo, la implementación de estos perfiles genéticos en la práctica clínica tiene limitaciones, sobre todo en nuestro país, por su alto costo.…”

The recent progress of neoadjuvant chemotherapy in triple negative breast cancer: A short review

“…NACT also offers the clinician two significant information: response to treatment thus enabling the appropriate design of subsequent therapies and prognostic information for the patient. It is now acceptable that patients who achieve pathological complete response (pCR) after NACT appear to have significantly lower recurrence rate in comparison to those with residual disease upon surgery [19][20][21] . This is particularly true for patients with TNBC [20,22] and those with HER2-positive tumors treated with trastuzumab [21] .…”

“…It is now acceptable that patients who achieve pathological complete response (pCR) after NACT appear to have significantly lower recurrence rate in comparison to those with residual disease upon surgery [19][20][21] . This is particularly true for patients with TNBC [20,22] and those with HER2-positive tumors treated with trastuzumab [21] . The last finding provides one more use for NACT: that of allowing investigators to examine efficacy of new chemotherapeutic regimens, as well as the modulation of biomarkers from initial biopsy to definitive surgery in order to gain approval for new treatments.…”